

A highly susceptible hACE2-transgenic mouse model for SARS-CoV-2 research

Gang Liu^{1†}, Min Zhang^{1†}, Baolei Wu^{2†}, Cheng Zhang^{3,4}, Yan Wang⁵, Xuelian Han¹, Rongjuan Wang⁶, Li Li⁵, Yuwei Wei¹, Yali Sun^{1,7}, Xiangwen Cao^{1,7}, Yuan Wang¹, Yalan Li⁶, Min Li¹, Guangyu Zhao^{1,7}, Yuehua Ke^{8*}, Zhendong Guo^{3,4*}, Qi Yin^{1*}, Yansong Sun^{1*}

¹State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China

²Vanke School of Public Health, Tsinghua University, Beijing, China

³Changchun Veterinary Research Institute, Chinese Academy of Agriculture Sciences, Changchun, Jilin, China

⁴College of Veterinary Medicine, Hebei Agricultural University, 2596 Lucky South Street, Baoding, Hebei, China

⁵SPF (Beijing) Biotechnology Co., Ltd. Beijing, China

⁶Beijing Kohnoor Science & Technology Co. Ltd, Beijing, China

⁷Public Health School, Mudanjiang Medical University, Mudanjiang, China


⁸Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China

*Correspondence:


Yansong Sun, sunys@qq.com; Qi Yin, jnyzyinqi@163.com; Zhendong Guo, guozd@foxmail.com; Yuehua Ke, yuehuakebj@163.com

[†]These authors contributed equally to this work and share first authorship.

Supplementary figures.



Supplementary Figure 1. The binding kinetics of two antibodies to SARS-CoV S1 recombinant proteins measured by BLI.



Supplementary Figure 2. Prophylactic and therapeutic effects of two antibodies, MW06 (RBD antibodies), and mCD24-MW06 (CD24-conjugated RBD antibodies), against low-dose SARS-CoV-2 infection. **(A)** Survival curve of hACE2-Tg mice treated with MW06 or mCD24-MW06 before SARS-CoV-2 infection. **(B)** Changes of body weight of hACE2-Tg mice treated with MW06 or mCD24-MW06 before SARS-CoV-2 infection. (n=5 per group). **(C)** Survival curve of hACE2-Tg mice treated with MW06 or mCD24-MW06 after SARS-CoV-2 infection. **(D)** Changes of body weight of hACE2-Tg mice treated with MW06 or mCD24-MW06 after SARS-CoV-2 infection. (n=5 per group).